These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 33409397)

  • 21. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
    Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities.
    Idalsoaga F; Kulkarni AV; Mousa OY; Arrese M; Arab JP
    Front Med (Lausanne); 2020; 7():448. PubMed ID: 32974366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics.
    Huang G; Wallace DF; Powell EE; Rahman T; Clark PJ; Subramaniam VN
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893185
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
    World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The genetic backgrounds in nonalcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Itoh Y
    Clin J Gastroenterol; 2018 Apr; 11(2):97-102. PubMed ID: 29492830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease.
    Anstee QM; Seth D; Day CP
    Gastroenterology; 2016 Jun; 150(8):1728-1744.e7. PubMed ID: 26873399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential epigenetic mechanism in non-alcoholic Fatty liver disease.
    Sun C; Fan JG; Qiao L
    Int J Mol Sci; 2015 Mar; 16(3):5161-79. PubMed ID: 25751727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
    Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NAFLD: genetics and its clinical implications.
    Sharma D; Mandal P
    Clin Res Hepatol Gastroenterol; 2022 Nov; 46(9):102003. PubMed ID: 35963605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic determinants of alcoholic liver disease.
    Stickel F; Hampe J
    Gut; 2012 Jan; 61(1):150-9. PubMed ID: 22110053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers.
    Krawczyk M; Bantel H; Rau M; Schattenberg JM; Grünhage F; Pathil A; Demir M; Kluwe J; Boettler T; Weber SN; Geier A; Lammert F;
    J Hum Genet; 2018 May; 63(5):621-626. PubMed ID: 29483677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD).
    Podrini C; Borghesan M; Greco A; Pazienza V; Mazzoccoli G; Vinciguerra M
    Curr Pharm Des; 2013; 19(15):2737-46. PubMed ID: 23092327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural history of NASH.
    Armandi A; Bugianesi E
    Liver Int; 2021 Jun; 41 Suppl 1(Suppl 1):78-82. PubMed ID: 34155792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis of non-alcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H
    Diabetologia; 2016 Jun; 59(6):1104-11. PubMed ID: 27091184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition.
    Lee JH; Friso S; Choi SW
    Nutrients; 2014 Aug; 6(8):3303-25. PubMed ID: 25195642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-alcoholic fatty liver disease and risk of type 2 diabetes.
    Lallukka S; Yki-Järvinen H
    Best Pract Res Clin Endocrinol Metab; 2016 Jun; 30(3):385-95. PubMed ID: 27432073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.
    Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Gustot T; Deviere J; Debette S; Amouyel P; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
    Int J Cancer; 2019 Feb; 144(3):533-544. PubMed ID: 30289982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease.
    Robinson KE; Shah VH
    Transl Gastroenterol Hepatol; 2020; 5():49. PubMed ID: 33073044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables.
    Vespasiani-Gentilucci U; Gallo P; Dell'Unto C; Volpentesta M; Antonelli-Incalzi R; Picardi A
    World J Gastroenterol; 2018 Nov; 24(43):4835-4845. PubMed ID: 30487694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modifiers of Liver-Related Manifestation in the Course of NAFLD.
    Nasr P; Blomdahl J; Kechagias S; Ekstedt M
    Curr Pharm Des; 2020; 26(10):1062-1078. PubMed ID: 32156227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.